International Assets Investment Management LLC Invests $1.83 Million in CRISPR Therapeutics AG (NASDAQ:CRSP)

International Assets Investment Management LLC bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 38,852 shares of the company’s stock, valued at approximately $1,825,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Capital International Investors lifted its position in shares of CRISPR Therapeutics by 27.8% during the first quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock worth $534,175,000 after purchasing an additional 1,702,624 shares in the last quarter. Vanguard Group Inc. boosted its position in CRISPR Therapeutics by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock valued at $111,564,000 after buying an additional 46,148 shares during the period. SR One Capital Management LP acquired a new position in shares of CRISPR Therapeutics in the first quarter worth $71,496,000. Dimensional Fund Advisors LP increased its position in shares of CRISPR Therapeutics by 2.1% during the second quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company’s stock worth $51,326,000 after acquiring an additional 19,094 shares during the period. Finally, Farallon Capital Management LLC acquired a new stake in shares of CRISPR Therapeutics in the second quarter valued at $28,625,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Trading Up 9.4 %

Shares of CRSP opened at $50.76 on Monday. The company’s 50 day simple moving average is $47.15 and its 200-day simple moving average is $52.32. The firm has a market cap of $4.32 billion, a PE ratio of -15.72 and a beta of 1.67. CRISPR Therapeutics AG has a 12-month low of $43.42 and a 12-month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The business had revenue of $0.52 million for the quarter, compared to the consensus estimate of $12.31 million. During the same quarter in the prior year, the firm earned ($0.98) earnings per share. The business’s revenue was down 99.3% compared to the same quarter last year. As a group, equities research analysts forecast that CRISPR Therapeutics AG will post -5.57 EPS for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the sale, the general counsel now directly owns 62,597 shares of the company’s stock, valued at $2,896,989.16. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the transaction, the general counsel now directly owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the transaction, the chief executive officer now owns 226,540 shares of the company’s stock, valued at approximately $10,484,271.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on CRSP shares. Chardan Capital cut their price target on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Stifel Nicolaus decreased their price target on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Barclays lowered their price target on shares of CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating for the company in a report on Tuesday, August 6th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research report on Tuesday, October 29th. Finally, Truist Financial lowered their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, CRISPR Therapeutics has an average rating of “Hold” and an average price target of $75.19.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.